LEHI, UTAH / ACCESSWIRE / November 12, 2019 / Frelii, Inc. (OTC PINK:FRLI) ("Frelii" or the "Company"), a biotechnology company working to commercialize its patent-pending DNA gene sequencing ...
FDA Approves Subcutaneous Formulation of Actemra for Use in Active Systemic Juvenile Idiopathic Arthritis (SJIA), a Rare Form of Juvenile Arthritis September 13, 2018 11:35 AM Eastern Daylight Time ...
Please provide your email address to receive an email when new articles are posted on . The FDA has approved a self-injectable formulation of Benlysta for patients with systemic lupus erythematosus, ...
The Wasan Laboratory in the Faculty of Pharmaceutical Sciences at the University of British Columbia in partnership with iCo Therapeutics Inc. (Vancouver BC, Canada) have developed a novel oral ...
Biological role of TUSC3 in non-small-cell lung cancer. This is an ASCO Meeting Abstract from the 2018 ASCO Annual Meeting I. This abstract does not include a full text component.
Huonslab, the R&D subsidiary of Huons Global, secured patents and PCT filings for 11 SC antibody formulations using HyDIFFUZE™.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced the publication of new data in the journal Molecular Therapy by ...
Highly potent but poorly water-soluble drug (PWSD) candidates are common outcomes of contemporary drug discovery programmes. These lipophilic compounds often exhibit poor systemic exposure following ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results